Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

This is a a phase III, randomized, open-label clinical trial comparing endocrine therapy combined with high-dose palbociclib and hydroxychloroquine to endocrine therapy combined with standard-dose palbociclib for hormone receptor-positive and her2-negative advanced breast cancer.

NCT Number	NCT07061717
Lead Sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Enrollment	474 participants
Start Date	2025-07-01
Primary Completion	2029-07-01 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-11